年表作成・共有サービス - pastport

STA Pharmaceutical Co., Ltd., (“WuXi STA”) , a leading Contract Development and Manufacturing Organization, announces that it has received 2021 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service. This is the seventh time that WuXi STA has won the “CMO Leadership Awards” and the second time being recognized in all six core categories, which fully recognizes the outstanding achievements and contributions by WuXi STA in building quality system meeting global regulatory standards and providing efficient, flexible and high-quality solutions with integrated CMC (Chemical, Manufacturing, and Control) services.

For the 2021 CMO Leadership Awards, Life Science Leader Magazine teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers, aiming to recognize the top contract manufacturing organizations (CMOs) achieving outstanding performance in terms of capabilities, expertise, quality, etc., to set a benchmark in the industry. More than 70 contract manufacturers were assessed by 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey, covering all sizes of companies from both Pharma and Biopharma industries. In 2021, WuXi STA achieved the top overall honor in all six core categories based on customers’ direct experience and great feedback working with WuXi STA.

WuXi STA has been deeply involved in the CDMO industry for more than ten years. In the year of 2020 alone, WuXi STA served more than 470 customers worldwide, supporting 13 NDA approvals globally including 5 from US FDA, 4 from EU EMA, 2 from China NMPA and 2 from Japan PMDA. Dr. Minzhang Chen, CEO of WuXi STA, commented: “Thanks to our partners for their recognition of WuXi STA, and we will continue to leverage our end-to-end CMC platform, along with the global standard quality systems to empower more partners to accelerate their pathway to market for the benefit of global patients.”

1. Formulation development#